Abnormally elevated serum p2-microglobulin has been associated with progression of human immunodeficiency virus (HIV) disease and could reflect in vivo HIV activity. We prospectively studied the effect of azidothymidine therapy on serum p2-microglobulin concentration in 41 patients with AIDS or AIDS-related complex. Median p2-microglobuIin concentration decreased from 4.02 mg/L before therapy to 3.73 mg/L at week 24 of therapy (P =.016). Individual changes in p2-microglobulin during azidothymidine therapy correlated with changes in serum HIV p24 antigen (Spearman, r =.42, P =.007). Also, in a randomized placebo-controlled study, median [)2-microglobulin concentration decreased after 16 w of therapy in 5 azidothymidine-treated patients compared with levels in 7 placebo-treated controls (P =.05). Serum p2-microglobulin appears to be a sensitive marker for in vivo antiretroviral drug activity and may be a better marker than serum p24 antigen for early intervention trials involving antiretroviral agents.
ASJC Scopus subject areas
- Infectious Diseases
- Immunology and Allergy
- Public Health, Environmental and Occupational Health